The discrimination of the MPN samples was not dependent on the driver mutation, which is underlined by our finding that CALR-, MPL-mutated, or triple-negative patients did not differ in the PCA or heatmaps from JAK2-mutated samples. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.